Association between IGF-1 levels and MDD: a case-control and meta-analysis
Authors:
Open Access
- 11 June 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 15, 1396938
Abstract
Purpose: Insulin-like growth factor-1 (IGF-1) has a variety of neurotrophic effects, including neurogenesis, remyelination and synaptogenesis, and is an effective regulator of neuronal plasticity. Although multiple studies have investigated IGF-1 in depression-related disorders, few studies have focused on patients with a first episode of clearly diagnosed depression who had never used antidepressants before. Therefore, this study investigated first-episode and drug-naïve patients with depression to supplement the current evidence around IGF-1 levels in depressive disorders.Patients and methods: This study consisted of two parts. In the first part, 60 patients with first-episode and drug-naïve depression and 60 controls matched for age, sex, and BMI were recruited from the outpatient department of the Fourth Hospital of Wuhu City, and the community. The case-control method was used to compare differences in serum IGF-1 levels between the two groups. In the second part, 13 case-control studies were screened through the database for meta-analysis to verify the reliability of the results.Results: Results of the case-control study demonstrated that serum IGF-1 levels are significantly higher in patients with first-episode and drug-naïve depression compared to healthy controls (p<0.05), although there was no significant difference between men and women with diagnosed MDD, there was no significant correlation between serum IGF-1 level and age in patients with depression and no significant correlation between IGF-1 level and the severity of depression. The meta-analysis corroborates these findings and demonstrated that IGF-1 levels are significantly higher in MDD patients than in healthy controls.Conclusion: Patients with first-episode and drug-naïve depression have higher IGF-1 levels, but the exclusion of confounding factors in studies of IGF-1 as it relates to depressive disorders must be taken into consideration strictly, and additional research is needed to fully understand the critical role of IGF-1 in depression.Systematic review registration: PROSPERO, identifier CRD42023482222.Keywords
This publication has 37 references indexed in Scilit:
- Association between insulin resistance and serum insulin-like growth factor 1 levels in patients with non-remitting major depressive disorderJournal of Affective Disorders, 2023
- Serum cytokines-based biomarkers in the diagnosis and monitoring of therapeutic response in patients with major depressive disorderInternational Immunopharmacology, 2023
- Cerebrospinal Fluid Biomarkers in Patients With Unipolar Depression Compared With Healthy Control IndividualsJAMA Psychiatry, 2022
- Value of peripheral neurotrophin levels for the diagnosis of depression and response to treatment: A systematic review and meta-analysisEuropean Neuropsychopharmacology, 2020
- Major depressive disorder and accelerated aging from a peripheral IGF-1 overexpression perspectiveMedical Hypotheses, 2020
- Central IGF-1 protects against features of cognitive and sensorimotor decline with aging in male miceGeroScience, 2019
- IGF-I in major depression and antidepressant treatment responseEuropean Neuropsychopharmacology, 2015
- Mind over hormones; Sex differences in associations of well-being with IGF-I, IGFBP-3 and physical activity in the KORA-Age studyExperimental Gerontology, 2014
- IGF-I levels and depressive disorders: Results from the Study of Health in Pomerania (SHIP)European Neuropsychopharmacology, 2014
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002